Emergence of Ceftolozane-Tazobactam Resistant Pseudomonas aeruginosa During Treatment is Mediated by a Single AmpC Structural Mutation [PublishAheadOfPrint]

Ceftolozane-tazobactam is a cephalosporin β-lactamase-inhibitor combination that exhibits potent in vitro activity against Pseudomonas aeruginosa, including strains resistant to other β-lactams. Emergence of ceftolozane-tazobactam resistance has rarely been described among clinical isolates of P. aeruginosa. Here we characterized ceftolozane-tazobactam resistant P. aeruginosa strains that were recovered from a patient treated with this agent for 6 weeks for a recurrent wound infection. The result showed that the resistance is mediated by a single AmpC structural mutation.

http://ift.tt/2xGt6Nl